Latest research

Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.

The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.

Researchers have investigated how long it takes for disease modifying drugs to be fully effective at reducing relapses and slowing progression.

This study compared the effectiveness of amantadine, modafinil and methylphenidate with placebo in people with MS-related fatigue.

The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.

There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.

Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.

The MS Trust is very disappointed that NICE does not recommend ozanimod (Zeposia) as an NHS treatment in England and Wales.

A potential treatment for multiple sclerosis uses mRNA technology, similar to two of the Covid-19 vaccines. Find out more about this research.

In this study, researchers compared daytime sleepiness while driving in people with and without MS.

Most people with MS will have heard of demyelination but perhaps not remyelination. We spoke with Dr Nick Cunniffe, who has been involved in some of the recent remyelination research, to find out more.

There's been a lot of interest around the new Covid-19 vaccines and how they might affect people with multiple sclerosis (MS). We've collected some common questions and answers from the MS Trust Enquiry Service this week to share with you.